2021 | HFSA

HFSA Announces Late Breaking Clinical Trials Coming to HFSA 2021

HFSA News HFSA Annual Scientific Meeting

HFSA is pleased to announce the Late Breaking Clinical Trials coming to HFSA 2021. Where will you and your heart failure team be on September 12 and 13? Block your calendars now so you don’t miss two Late Breaking Clinical Trials Sessions that provide a dive deep into the latest rapidly evolving research in the field of heart failure:

  • Sunday, September 12 at 9:45 – 11:15 AM MT
  • Monday, September 13 at 11:00 AM – 12:00 PM MT

The following Late Breaking Clinical Trials Presentations will take place at the HFSA Annual Scientific Meeting 2021 in-person, via livestream, and OnDemand post-session:

  • The Impact of Sacubitril-valsartan Vs. Ramipril On Health Status Post Myocardial Infarction: A PARADISE-MI Analysis
  • Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure with Reduced Ejection Fraction: Insights from The GALACTIC-HF Trial
  • Redwood-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy
  • Effects of Dapagliflozin On Symptoms, Function and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction - Main Results from The PRESERVED-HF Trial
  • Effect of Empagliflozin On Worsening Heart Failure Events in Patients with Heart Failure and A Preserved Ejection Fraction: The Emperor-preserved Trial
  • Finerenone in Mild to Severe Chronic Kidney Disease and Type 2 Diabetes: The Fidelity Analysis
  • The Association of Digital Tool Use and Heart Failure Care: Insights from The Connect-hf Trial
  • A Mobile Health Intervention to Increase Physical Activity in Patients with Heart Failure and Diabetes: The Target-hf-dm Randomized Controlled Trial
  • Results from First-In-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease